앨라배마의 다발성 골수종 임상 시험
다발성 골수종 관련 연구 22개가 앨라배마 내 여러 지역에서 참여자를 모집하고 있습니다.
앨라배마의 도시
공식 연구 텍스트(영어)
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- Infirmary Cancer Care, Mobile
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 12. 업데이트됨 · NCT06152575A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- University of Alabama Birmingham, Birmingham
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 11. 3. 업데이트됨 · NCT04634552A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
- Clearview Cancer Institute, Huntsville
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 10. 30. 업데이트됨 · NCT07284758A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
- University of Alabama at Birmingham, Birmingham
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 10. 29. 업데이트됨 · NCT06615479A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
- Gulf Health Hospitals, Inc. d/b/a Infirmary Cancer Care - Malbis, Daphne
- Gulf Health Hospitals, Inc. d/b/a Thomas Medical Center, Daphne
- Gulf Health Hospitals, Inc. d/b/a Infirmary Cancer Care - Fairhope, Fairhope
- 외 4개
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 10. 27. 업데이트됨 · NCT05623020A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- University of Alabama At Birmingham Hospital, Birmingham
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 10. 26. 업데이트됨 · NCT04973605A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
- Infirmary Health - Diagnostic & Medical Clinic (DMC), Mobile
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 10. 13. 업데이트됨 · NCT06980480AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
- Research Site, Birmingham
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 10. 8. 업데이트됨 · NCT05850234Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- University of Alabama at Birmingham, Birmingham
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 10. 6. 업데이트됨 · NCT06297226A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Alabama Oncology, Birmingham
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT07518186A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
- University of Alabama at Birmingham Hospital, Birmingham
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 9. 23. 업데이트됨 · NCT07116616TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham
피험자 모집 중2상
12세 이상 · 모든 성별 · 2026. 9. 22. 업데이트됨 · NCT02693535A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
- University of Alabama at Birmingham, Birmingham
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 9. 2. 업데이트됨 · NCT06988488A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
- University of Alabama at Birmingham, Birmingham
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 7. 16. 업데이트됨 · NCT06121843Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
- University of Alabama at Birmingham, Birmingham
피험자 모집 중2상
19세 이상 · 모든 성별 · 2026. 6. 4. 업데이트됨 · NCT06974786A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
- GSK Investigational Site, Mobile
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 4. 22. 업데이트됨 · NCT06679101A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
- University of Alabama at Birmingham, Birmingham
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 3. 18. 업데이트됨 · NCT06153251Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)
- University of Alabama at Birmingham, Birmingham
피험자 모집 중2상
18세 이상 · 모든 성별 · 2025. 12. 31. 업데이트됨 · NCT04991103Prehabilitation Feasibility Among Older Adults Undergoing Transplantation
- Kirklin Clinic of UAB Hospital, Birmingham
피험자 모집 중
60세 이상 · 모든 성별 · 2025. 12. 24. 업데이트됨 · NCT05642884Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry
- Kirklin Clinic of UAB Hospital, Birmingham
피험자 모집 중관찰 연구
50세 이상 · 모든 성별 · 2025. 12. 8. 업데이트됨 · NCT05556928CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
- University of Alabama at Birmingham, Birmingham
피험자 모집 중1상
18세 이상 · 모든 성별 · 2025. 9. 25. 업데이트됨 · NCT05722418A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
- UAB Comprehensive Cancer Center, Birmingham
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2025. 9. 5. 업데이트됨 · NCT05372354ClinicalTrials.gov 출처, 2026. 11. 15. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.